Comparing Lifecore Biomedical (NASDAQ:LFCR) & Wright Medical Group (OTCMKTS:GCVRZ)

Wright Medical Group (OTCMKTS:GCVRZ) and Lifecore Biomedical (NASDAQ:LFCR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Wright Medical Group and Lifecore Biomedical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wright Medical Group	0	0	0	0	0.00
Lifecore Biomedical	1	2	1	0	2.00

Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 49.25%. Given Lifecore Biomedical’s stronger consensus rating and higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than Wright Medical Group.

Profitability

This table compares Wright Medical Group and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Wright Medical Group	N/A	N/A	N/A
Lifecore Biomedical	-25.43%	N/A	-14.40%

Insider & Institutional Ownership

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Wright Medical Group and Lifecore Biomedical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wright Medical Group	N/A	N/A	N/A	N/A	N/A
Lifecore Biomedical	$128.87 million	1.27	-$35.26 million	($0.94)	-4.63

Wright Medical Group has higher earnings, but lower revenue than Lifecore Biomedical.

Summary

Lifecore Biomedical beats Wright Medical Group on 6 of the 8 factors compared between the two stocks.

About Wright Medical Group

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia in adults and children; and Cablivi to treat acquired thrombotic thrombocytopenic purpura in adults. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, for hematologic malignancies; and Zaltrap, for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, a sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; consumer healthcare products for allergy, cough, cold, pain, nutrition, digestion, and others; and pediatric, influenza, adult and adolescent booster, meningitis, travel, and endemic vaccines. Sanofi was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.